Cellular therapy (Frischzellentherapie)

injection · 1931–1971

category:injection

delivery:Subcutaneous or intramuscular injection of macerated tissue from a freshly killed lamb fetus, with the donor organ selected to correspond to the recipient organ targeted for rejuvenation.

price tier:not classified

era:1931–1971

current status:historical

regulatory:grey_market

SHORT PITCH (AS SOLD)

Injection of fresh cells from organs of freshly killed lamb fetuses, claimed to restore the corresponding organs in the recipient and slow biological aging.

THE ACTUAL EVIDENCE

No controlled trial has demonstrated efficacy on any objective endpoint, and no evidence demonstrates organ-specific migration, durable integration, or restoration after injection. A 2015 Swissmedic and FOPH assessment found no scientifically demonstrated efficacy and listed substantial risks: hypersensitivity, injection-site abscess and sepsis, zoonotic infection, autoimmune disease, and reported deaths. Live animal-cell use requires Swiss federal authorization; the authorities said no relevant authorization had been granted.

PRACTITIONERS

Paul Niehans

INGREDIENTS

Fetal sheep cells

CASES

niehans-fetal-cells-1931-1971

CLAIMS

Injection of fetal sheep cells from a specific organ restores the function and structure of the corresponding aging organ in the recipient through migration and integration of the donor cells. untested
Cellular therapy as administered at Clinique La Prairie is safe; fresh fetal cells do not provoke meaningful immune rejection in human recipients and present no significant adverse-event risk. refuted
Cellular therapy administered to a recipient of advanced age restores youthful function and reverses the visible and felt effects of biological aging. untested
Cellular therapy administered to Pope Pius XII in 1954 resolved his chronic gastric crisis and produced clinical improvement attributable to the treatment. untested

SOURCES

NOTES

Cellular therapy, in the Niehans formulation, is the subcutaneous or intramuscular injection of macerated tissue from a freshly killed lamb fetus. Donor organs are selected to correspond to the recipient organ targeted for therapeutic effect. The protocol was developed at Clinique La Prairie in Clarens, Switzerland, beginning in 1931. It was never demonstrated in a controlled trial. Swissmedic and the FOPH reported in 2015 that no relevant fresh-cell product or use had received Swiss authorization and that live animal-cell procedures require federal authorization as xenotransplantation. The practice is a historical comparison point for later biological-substance-transfer interventions; that structural parallel does not establish direct descent or present continuation of Niehans’s protocol.